Radiobiology & cancer

Study on:
1. How high doses of radiotherapy (SBRT, IORT and HDR) could trigger immune stimulation through modulation of cytokines and immune cells in plasma.
2. Predictive radiation sensitivity tests.
3. New therapeutic strategies in brachytherapy.
4. New therapeutic strategies in external radiotherapy.
5. Evaluation of quality of life in the treatment of prostate cancer.
6. Application of intracranial stereotactic radiotherapy (SRT) and
7. Stereotactic body radiotherapy (SBRT) techniques.

• Strnad,V;Polgár,C;Ott,OJ;Hildebrandt,G;Kauer Dorner,D;Knauerhase,H;Major,T et al, Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial, Lancet Oncol., 2023;24(3):doi:10.1016/S1470-2045(23)00018-9
• Hannoun Levi,JM;Gal,J;Polgar,C;Strnad,V;Loessl,K;Polat,B;Kauer Domer,D et al, Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor, Int. J. Radiat. Oncol. Biol. Phys., 2023;117(5):doi:10.1016/j.ijrobp.2023.06.075
• Pons Riverola,A;Morillas,H;Berdejo,J;Pernas,S;Pomares,H;Asiain,L;Garay,A et al, Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments., Cancers, 2023;15(24):doi:10.3390/cancers15245885
• Garcia Exposito,N;Ramos,R;Navarro Perez,V;Molina,K;Arnaiz,MD;Padrones,S;Ruffinelli,JC et al, Stereotactic Body Radiotherapy versus Surgery for Lung Metastases from Colorectal Cancer: Single-Institution Results, Cancers, 2023; 15(4): doi:10.3390/cancers15041195
• Garcia Tejedor,A;Ortega Exposito,C;Salinas,S;Luzardo Gonzalez,A;Falo,C;Martinez Perez,E; Perez Montero,H et al, Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial), Front. Oncol., 2023;131184021-1184021, doi:10.3389/fonc.2023.1184021

• MCI22002. RADIOTERAPIA DE PRECISIÓN: FIRMA MOLECULAR PREDICTIVA PARA RADIOSENSIBILIDAD EN CÁNCER DE MAMA. Ministerio de Ciencia e Innovación. Budget: 110.013€. 2022-2025. PI: GUEDEA EDO, FERRAN.
• AGA23009. Programa Investigo de contractació de persones joves demandants d’ocupació en la realització d’iniciatives de recerca i innovació (INVESTIGO 2023). AGENCIA GESTIO D'AJUTS UNIV. I RECERCA. Budget: 66217,84. 2023-2025. PI: GUEDEA EDO, FERRAN.
• 2023-018-1. A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma. NANOBIOTIX. Budget: 42.534€. 2022- . PI: Linares Galiana, Isabel.
• 16PNJ017. Detection of systemic immune response in peripheral blood proveided by high radiation doses delivered over lung in stereostatic conditions. 2016- . PI: Navarro Martín, Arturo.
• 16ACL044. ESTUDIO DE FASE 3 ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE JNJ-56021927 EN SUJETOS CON CÁNCER DE PRÓSTATA LOCALIZADO O LOCALMENTE AVANZADO Y DE ALTO RIESGO QUE ESTÁN RECIBIENDO TRATAMIENTO CON RADIOTERAPIA PRIMARIA. Janssen-Cilag, S.A. 2016- . PI: Boladeras Inglada, Ana Mª.

We currently have three industry-funded projects under way:

Immune modulation through brachytherapy in blood and tumour microenvironment.
Detection of systemic immune response to peripheral blood provided by high doses of radiation given to the lung in stereotactic conditions.
INTRABEAM: precision hypofractionated radiotherapy with immune-system response.
Over the past five years, we have obtained two competitive projects, Healthcare Research and Development Strategy grants:
Long-term effectiveness: 10-year follow-up of the “Spanish Multicentre Study of Localised Prostate Cancer” cohort (PI13 / 00412).
Efficacy of new treatments for low-risk localised prostate cancer: a randomised clinical trial (PI13 / 00412).